Pharma

Your Article Summary

See Latest Articles

Introducing deCODEme Cardio and deCODEme Cancer
deCODE genetics, 05/15/09

Through deCODEme, the world's first first retail genome analysis service, deCODE genetics announced the launch of the first focused genetic scans for assessing personal risk of several major cardiovascular diseases and common cancers. deCODEme Cardio, which detects genetic risk factors for heart attack, stroke and atrial fibrillation, peripheral artery disease, and several other conditions, is offered at an introductory price of $195. deCODEme Cancer measures genetic risk factors for prostate, lung, bladder, skin and colorectal cancers, as well as the common form of breast cancer, at an introductory price of $225. Both can be ordered as a bundle for $350.

Today in Medical Devices/Products...keeping you current

Receive free subspecialty "5-minute updates" via email

Covidien Announces Definitive Agreement to Sell U.S. Radiopharmacies
Covidien, 12/18/09

Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09

FDA Advisory Committee Supports Use of Aztreonam for Inhalation Solution for Patients with Cystic Fibrosis
Gilead, 12/14/09

 See all of Medical Devices/Products